Jin10 Data reported on October 31 that Danish pharmaceutical company Novo Nordisk (NVO.N) initiated an active acquisition of obesity drug developer Metsera on Thursday, with a bid of up to $9 billion, aiming to surpass Pfizer's (PFE.N) $7.3 billion deal reached last month, which may trigger legal action against this biotechnology company. The company proposed to acquire Metsera for $56.50 per share in cash, with an additional payment of $21.25 per share if specific milestones are achieved. Metsera stated in a separate announcement that Novo Nordisk's new offer is better than Pfizer's proposal. According to the protocol, Pfizer now has four days to modify the original proposal, and if Metsera ultimately determines that the new offer is superior, it has the right to terminate the agreement with Pfizer. Following the announcement, Metsera's stock price soared over 20%, with a cumulative rise of 78% over the past three months, while Novo Nordisk's stock price in Copenhagen fell nearly 4%.